Comparative Pharmacology
Head-to-head clinical analysis: ALTRENO versus AMNESTEEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTRENO versus AMNESTEEM.
ALTRENO vs AMNESTEEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; believed to involve reduction of hepatic glucose production and improvement of insulin sensitivity via AMPK activation.
Retinoid that binds to and activates retinoic acid receptors (RARs), thereby normalizing keratinocyte differentiation and reducing sebum production.
ALTRENO is not a recognized drug. No data available.
0.5-1.0 mg/kg/day orally in 2 divided doses
None Documented
None Documented
Terminal elimination half-life is 20-30 hours; steady state reached in 5-7 days.
Terminal elimination half-life: 10-20 hours (mean 17 hours) in patients with normal renal function; prolonged in severe renal impairment
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal elimination.
Renal (65-83% as unchanged drug and metabolites), fecal (15-35% as metabolites)
Category C
Category C
Retinoid
Retinoid